《大行》花旗降三生制药(01530.HK)目标价至34.4元 行业反腐影响预测下调

阿斯达克财经
Yesterday

花旗发表研究报告指出,三生制药(01530.HK) 中期收入按年增长4%至45.3亿元人民币,受增值税税率变动及行业反贪腐行动影响,产品销售收入按年跌19%,惟期内录得SSGJ-707里程碑收入8.52亿元人民币。花旗预料增值税税率上调的影响将于下半年持续,但对2027至2028年产品销售前景正面,主要受新产品上量带动。辉瑞已就707开展9项全球临床试验,上半年已启动两项三期研究,计划下半年再启动...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10